Who
William P. Quinn
President, CEO and CFO
Company insider
Files Form 4 as: President, CEO and CFO, Bolt Biotherapeutics; CFO,Sr.V.P. Finance, Corp.Dev., Sunesis Pharmaceuticals.
In numbers
- Trades disclosed
- 55
- Buys
- 17
- Sells
- 3
- Bought
- $120K
- Sold
- $117K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 30 Nov 2017
- Last trade
- 18 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $30K9,132 at $3.24 | filing |
| 18 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $30K9,132 at $3.24 | filing |
| 17 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $22K6,545 at $3.32 | filing |
| 17 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $22K6,545 at $3.32 | filing |
| 16 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $7,1291,889 at $3.77 | filing |
| 16 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $7,1221,889 at $3.77 | filing |
| 5 Jun 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $2,469637 at $3.88 | filing |
| 5 Jun 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $2,472637 at $3.88 | filing |
| 28 Jan 2026filed 4 Feb 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 28 Jan 2026filed 4 Feb 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,614 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,614 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,927 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,927 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,000 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,499 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,499 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,499 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,499 | filing |
News
Bolt Biotherapeutics (NASDAQ:BOLT) and Applied Dna Sciences (NASDAQ:BNBX) Head-To-Head ReviewBOLT · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name William P. Quinn; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.